H2SITE
17.11.2022 09:01:40 CET | Business Wire | Press release
Hydrogen takes a new step as a for the energy transition thanks to H2SITE, which has launched the world's first membrane manufacturing plant to obtain hydrogen from ammonia or methanol, and separate hydrogen from low concentration gas blends. The new facility will industrialize the production of membranes, the technological heart of H2SITE, used in the construction of hydrogen production reactors and separators. Similar membranes made of palladium alloys had been so far very costly, fragile, and difficult to manufacture and scale. H2SITE has managed to overcome these obstacles.
Located in Loiu (Biscay Region, Spain), the new H2SITE plant has a production capacity of tens of thousands of membranes per year. For its construction, H2SITE has invested more than 3 million euros, which it plans to double in the coming years to increase production capacity.
“Once the first production line has been validated, our objective is to significantly increase the capacity of the plant, vertically integrate the manufacturing process of the membrane and build new plants to tackle new markets,” according to Andrés Galnares, CEO of H2SITE. "Our objective is to significantly increase the number of membranes produced each year for the next 3 years, which entails continuing to invest in production assets similar to those we have already installed and increasing their level of automation to further reduce our costs.”
In 2022, H2SITE has booked orders of more than 5 million euros. Galnares assures that the goal is to double that figure over the next year, reaching a workforce of more than 50 professionals.
Asier Rufino, CEO of TECNALIA Ventures and President of H2SITE, states that "at TECNALIA we have been working for 20 years on the development and scaling up of hydrogen technologies its entire value chain: production, distribution, transport, storage and end uses. Together with the Technical University of Eindhoven (TU/e), the technology H2SITE leverages on was created. Today, H2SITE has scaled the process, has industrialized it, and is managing to reduce its cost to be able to develop new use cases”.
“This plant reflects the success of more than 10 years of collaboration initiated by TECNALIA and TU/e and supported by the Public Administration. H2SITE brings it to a new level with the industrialization of a disruptive process thanks to the help of investors who believe that technology is a critical enabler for the energy transition, such as ENGIE New Ventures, Breakthrough Energy Ventures, EQUINOR Ventures and institutional investors from the Basque Country Capital Riesgo País Vasco and Seed Capital Bizkaia. Along with the team that we have created, we cannot wish for better partners at this time," says Galnares.
The membrane separators and reactors will help provide hydrogen with high purity and limited cost, with focus on hard to abate industry sectors and heavy land and maritime mobility.
H2SITE is currently hiring in Europe. To learn more, follow H2SITE on LinkedIn.
About H2SITE
H2SITE was created in 2019 and has an exclusive technology of reactors separators for the conversion of different raw materials into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release
Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 13:30:00 CET | Press release
MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on
Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 12:00:00 CET | Press release
New ThinkEdge devices deliver scalable, rugged, and versatile intelligence from gateway to high-performance edge for real-time insights Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
